Private Markets, Angel and Secondary Investing, Sacra

Sacra

Private Markets, Angel and Secondary Investing

Bringing transparency to private markets so investors, founders, and employees can build on conviction. Sacra delivers deeply researched insights on the private companies shaping tomorrow's markets. By surfacing the data, context, and operator perspective that are missing from private markets today, we help secondary buyers and sellers price equity accurately and unlock liquidity for the people building these businesses.

Private Capital Markets

<ul><li>Now, as they expand to cancer therapy selection and monitoring, they’re competing with Natera, Myriad Genetics, and Guardant Health.</li><li>Developed during co-founder &amp; CEO Oguzhan Atay’s quantitative cell biology PhD at Stanford, the core tech behind BillionToOne (founded 2016) counts DNA molecules in the blood using machine learning with 1,000x higher resolution to identify risk factors in single base-pair mutations—which the company productized into the UNITY Screen (2019), a test for conditions like cystic fibrosis, SMA and sickle cell disease with a single non-invasive blood draw rather than invasive amniocentesis.</li><li>Hitting 500,000 total prenatal tests processed in June, Sacra estimates BillionToOne generated $153M in revenue in 2024, up 113% YoY from $72M in 2023, with 60%+ gross margins, valued at $1B as of their $130M June 2024 Series D for a 6.5x revenue multiple on nearly $400M raised in total.</li></ul>

Now, as they expand to cancer therapy selection and monitoring, they’re competing with Natera, Myriad Genetics, and Guardant Health.Developed during co-founder &amp; CEO Oguzhan Atay’s quantitative cell biology PhD at Stanford, the core tech behind BillionToOne (founded 2016) counts DNA molecules in the blood using machine learning with 1,000x higher resolution to identify risk factors in single base-pair mutations—which the company productized into the UNITY Screen (2019), a test for conditions like cystic fibrosis, SMA and sickle cell disease with a single non-invasive blood draw rather than invasive amniocentesis.Hitting 500,000 total prenatal tests processed in June, Sacra estimates BillionToOne generated $153M in revenue in 2024, up 113% YoY from $72M in 2023, with 60%+ gross margins, valued at $1B as of their $130M June 2024 Series D for a 6.5x revenue multiple on nearly $400M raised in total.

<ul><li>Benchling (founded 2012) found product-market fit with their “GitHub for experiments,” giving biotech researchers a way to digitize and streamline their experiment design, documentation, and sample tracking.</li><li>Benchling rode the wave of new modalities like CRISPR, gene therapy, and cell therapy moving out of academia and into professional labs in the mid-2010s.</li><li>Sacra estimates that Benchling hit $210M ARR in May 2024, up 27% year-over-year with 1,200 customers for an average of $175K per customer.</li></ul>

Benchling (founded 2012) found product-market fit with their “GitHub for experiments,” giving biotech researchers a way to digitize and streamline their experiment design, documentation, and sample tracking.Benchling rode the wave of new modalities like CRISPR, gene therapy, and cell therapy moving out of academia and into professional labs in the mid-2010s.Sacra estimates that Benchling hit $210M ARR in May 2024, up 27% year-over-year with 1,200 customers for an average of $175K per customer.

United States

Biotechnology company using AI models and in vivo data to discover better drugs for more patients

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Tahoe Therapeutics (THERAPEUTICS US)

BillionToOne At $153M/yr

TL;DR: Offering genetic testing to expecting mothers with a non-invasive blood draw rather than invasive amniocentesis, Sacra estimates...

Sacra

The $210M/year GitHub Of Biotech

TL;DR: Sacra estimates that Benchling hit $210M ARR in May 2024, up 27% year-over-year, with 1,200 customers for their GitHub for scientific...

Sacra

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)